Grail Inc. Announces CEO Transition

Healthcare company Grail Inc.’s Chief Executive Officer (CEO) Bob Ragusa will retire in June. The company’s current President, Josh Ofman, MD, MSHS, will serve as CEO upon Ragusa’s retirement.

In addition, Ofman has been appointed to Grail’s Board of Directors, effective immediately. Ofman’s appointment is the culmination of a succession planning process to ensure leadership continuity and strategic execution. Ragusa will remain on Grail’s Board until June 1, 2026, and plans to serve in a senior advisory role through March of 2027.

Greg Summe, Chairman of Grail’s board, said, “Josh brings a rare combination of industry leadership, health policy and reimbursement insight, and deep knowledge of Grail’s mission and strategy. Over his tenure as President, Josh has played a central role in shaping our strategy, advancing Galleri’s evidence program, and strengthening our clinical, regulatory and policy engagement efforts. His passion for improving patient outcomes and his proven ability to translate vision into results, coupled with expansion of his responsibilities as part of the succession planning process, position him to lead Grail’s next chapter of growth and impact for shareholders, customers, patients and employees alike.”

About Josh Ofman

Ofman joined Grail in 2019 and brings extensive experience in clinical medicine, biopharmaceutical leadership, health policy and precision medicine. He has served on numerous industry Boards, including BIO and the Precision Medicine Coalition.

Before joining Grail, Ofman spent more than 15 years at Amgen, most recently as Senior Vice President, Global Value, Access and Policy. Earlier in his career, he was a faculty member in the Department of Medicine and Health Services Research at the UCLA School of Medicine and the Division of Digestive Diseases at Cedars-Sinai Medical Center, and served as Senior Vice President of Zynx Health Inc., a subsidiary of Cerner Corp.

“What inspires me most about Grail is our bold ambition to solve one of society’s greatest public health challenges,” said Ofman. “We are leading the multi-cancer early detection field with the most comprehensive body of evidence and meaningful progress toward regulatory approval and reimbursement. I am honored to step into this role at a time of strong momentum and look forward to working alongside the exceptional team at Grail to accelerate our efforts to dramatically improve cancer screening so patients have more treatment options and more time with their loved ones.”